Study guide

11.1 Viral Hepatitis A to E

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

11.1 Viral Hepatitis A to E

Key Takeaways Explain This Topic AI

HBsAg positive with anti-HBc IgM indicates acute hepatitis B; HBsAg positive beyond six months with anti-HBc IgG indicates chronic infection.

Isolated anti-HBs positivity indicates vaccination, whereas anti-HBs with anti-HBc IgG indicates resolved natural infection.

Hepatitis E is the commonest cause of acute viral hepatitis in the UK and carries a high mortality in pregnancy and a chronic course in immunosuppressed patients.

Last updated: September 2026

Hepatology represents a cornerstone of the MRCP(UK) Part 1 examination. Candidates must master the interpretation of viral hepatitis serological matrices, the autoimmune serology and histopathology of autoimmune hepatitis, and the molecular genetics, clinical manifestations, diagnostic pathways, and targeted therapeutics of hereditary metabolic hepatopathies.

  • 1. Viral Hepatitis (A through E)
  • Hepatitis A Virus (HAV)

Virology & Transmission: Non-enveloped, single-stranded RNA picornavirus transmitted predominantly via the faecal-oral route through contaminated water or shellfish. Incubation period averages 2–6 weeks.

Clinical Presentation: Typically an acute, self-limiting illness manifesting with systemic prodromal symptoms (malaise, anorexia, low-grade fever, nausea), followed by dark urine, pale stools, tender hepatomegaly, and jaundice. Fulminant hepatic failure occurs in <0.5% of cases (higher in pre-existing chronic liver disease).

Diagnostic Serology:

Anti-HAV IgM: Appears at symptom onset, peaks within 2–3 weeks, and persists for 3–6 months. Diagnostic hallmark of acute Hepatitis A infection .

Anti-HAV IgG: Appears during convalescence and persists for life, conferring long-term immunity following natural infection or active immunization.

Clinical Caveat: Hepatitis A never causes chronic hepatitis or a chronic carrier state .

Hepatitis B Virus (HBV)

Virology & Transmission: Partially double-stranded circular DNA virus (Hepadnaviridae family) transmitted via percutaneous, sexual, and vertical (perinatal) exposure. Perinatal transmission carries a >90% risk of chronicity, whereas adult acquisition leads to chronic infection in only ~5% of immunocompetent hosts.

Serological Markers:

HBsAg (Hepatitis B Surface Antigen): The first serological marker to appear in acute infection (1–10 weeks post-exposure). Indicates the presence of active infection . Persistence beyond 6 months defines chronic Hepatitis B infection .

Anti-HBs (Hepatitis B Surface Antibody): Neutralizing antibody indicating immunity and recovery . Appears after clearance of HBsAg or following successful vaccination. A titre >=10 mIU/mL is considered protective.

Anti-HBc (Hepatitis B Core Antibody): Marker of exposure to the natural virus; never induced by recombinant Hepatitis B vaccination .

Anti-HBc IgM: Marker of acute infection or an acute severe flare of chronic HBV. Crucially, it serves as the sole serological marker during the "window period" (the interval when HBsAg has fallen below detectable thresholds but anti-HBs has not yet reached measurable levels).

Anti-HBc IgG: Persists indefinitely after natural exposure, signifying past resolved infection or ongoing chronic infection.

HBeAg (Hepatitis B e Antigen): Secretory protein derived from the pre-core/core gene; serves as an indirect surrogate for active viral replication and high infectivity .

Anti-HBe (Hepatitis B e Antibody): Indicates seroconversion to a state of lower viral replication and reduced infectivity (except in pre-core mutant strains).

HBV DNA (PCR): Direct quantitative measurement of viral load. Used to assess replication, guide initiation of antiviral therapy, and monitor therapeutic response.

Clinical Status HBsAg Anti-HBs Anti-HBc IgM Anti-HBc IgG HBeAg Anti-HBe HBV DNA Diagnostic Interpretation & Caveats

Acute Hepatitis B (Early / Active) Positive Negative Positive Negative / Low Positive Negative High (>10^5 IU/mL) Active acute infection; highly infectious; symptomatic acute phase

Window Period (Window Phase) Negative Negative Positive Negative / Low Negative Negative / Pos Low / Undetectable HBsAg cleared, anti-HBs not yet detectable; anti-HBc IgM is sole diagnostic marker

Chronic HBV (HBeAg-Positive / High Replication) Positive (>6 mo) Negative Negative Positive Positive Negative High (>20,000 IU/mL) High infectivity; active necroinflammation; high risk of progression to cirrhosis and HCC

Chronic HBV (HBeAg-Negative Inactive Carrier) Positive (>6 mo) Negative Negative Positive Negative Positive Low (<2,000 IU/mL) "Inactive carrier"; normal ALT; low transmission risk; still requires HCC surveillance if cirrhotic

HBeAg-Negative Chronic Hepatitis (Precore Mutant) Positive (>6 mo) Negative Negative Positive Negative Positive Moderately High (>2,000 IU/mL) Precore stop codon (G1896A) prevents HBeAg secretion despite active viral replication and necroinflammation

Resolved / Past Natural Infection Negative Positive Negative Positive Negative Positive / Neg Undetectable Cleared infection; cccDNA remains latent in hepatocyte nuclei; risk of reactivation during profound immunosuppression (e.g., rituximab)

Vaccinated State (Recombinant HBsAg) Negative Positive (>=10 mIU/mL) Negative Negative Negative Negative Undetectable Isolated anti-HBs; anti-HBc is strictly negative; confers lifelong immunological memory

Antiviral Management: Indications for treatment include HBV DNA >2,000 IU/mL with elevated ALT (>ULN) or evidence of significant fibrosis (>=F2). First-line therapies are oral nucleos(t)ide analogues with a high genetic barrier to resistance: Entecavir or Tenofovir (Tenofovir disoproxil fumarate [TDF] or Tenofovir alafenamide [TAF]; TAF is preferred in patients with renal impairment or osteoporosis). Pegylated Interferon-alpha-2a (48-week finite course) may be considered in young patients with mild disease and favorable genotypes.

Hepatitis C Virus (HCV)

Virology & Transmission: Enveloped, single-stranded RNA flavivirus transmitted predominantly via blood (intravenous drug use, contaminated blood products prior to 1991 screening, unsterile needle exposure). Chronicity develops in 75–85% of infected individuals .

Extrahepatic Manifestations: Mixed cryoglobulinaemia (Type II cryoglobulinaemia with palpable purpura, arthralgias, and membranoproliferative glomerulonephritis [MPGN]), porphyria cutanea tarda (PCT), lichen planus, Sjögren-like sialadenitis, and B-cell non-Hodgkin lymphoma.

Diagnostic Algorithm:

Anti-HCV Antibody: Initial screening immunoassay. Reflects exposure but cannot differentiate between active, chronic infection and resolved infection .

HCV RNA PCR (Qualitative / Quantitative): If anti-HCV is positive, reflex HCV RNA testing is mandatory. Presence of HCV RNA confirms active viraemic infection .

Therapy: Curative pan-genotypic Direct-Acting Antivirals (DAAs) administered orally for 8–12 weeks (e.g., Sofosbuvir + Velpatasvir or Glecaprevir + Pibrentasvir ). DAAs target the viral NS3/4A protease, NS5A replication complex, or NS5B RNA-dependent RNA polymerase, achieving a Sustained Virological Response at 12 weeks (SVR12) in >95% of patients , equivalent to virological cure.

Hepatitis D Virus (HDV)

Virology & Dependency: Defective, circular single-stranded RNA "delta agent" that lacks the genetic machinery to synthesize its own envelope proteins. It strictly requires Hepatitis B surface antigen (HBsAg) to assemble infectious virions and propagate .

Infection Patterns:

Co-infection: Simultaneous acquisition of HBV and HDV. Manifests as severe acute hepatitis with high risk of acute liver failure, but chronicity occurs in <5% of immunocompetent adults.

Superinfection: Acquisition of HDV in a patient already chronically infected with HBV. Triggers acute severe hepatitis, accelerates hepatic fibrosis, leads to cirrhosis in 70–80% of patients within 5–10 years, and significantly elevates the risk of hepatocellular carcinoma.

Diagnosis & Treatment: Detected via anti-HDV antibodies and HDV RNA PCR. Managed with Bulevirtide (entry inhibitor blocking NTCP receptor) or pegylated interferon-alpha.

Hepatitis E Virus (HEV)

Virology & Transmission: Non-enveloped single-stranded RNA hepevirus.

Genotypes 1 & 2: Transmitted via contaminated drinking water; causes major waterborne epidemics in developing countries.

Genotypes 3 & 4: Zoonotic transmission via consumption of undercooked pork, wild boar, or venison; prevalent in the UK and Europe.

Critical Exam Associations:

High Mortality in Pregnancy: In pregnant women (especially during the third trimester), acute HEV infection (Genotypes 1/2) carries a catastrophic 20–25% maternal mortality rate secondary to acute liver failure.

Chronic Hepatitis in Immunocompromised Hosts: In solid organ transplant recipients, haematological malignancy, or advanced HIV infection (CD4 <200), HEV (Genotype 3) can fail to clear, leading to chronic hepatitis and rapid development of cirrhosis within 2–3 years. Chronic HEV is treated by reducing immunosuppression and/or oral ribavirin for 12 weeks.